Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic CS1-specific universal CAR-expressing T lymphocytes UCARTCS1A

A preparation of allogeneic, off-the-shelf (OTS), universal transcription activator-like effector nuclease (TALEN)-engineered T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) human CS1 (CD2 subset 1; SLAM family member 7; SLAMF7; CD319; CRACC), with potential immunomodulating and antineoplastic activities. Upon transfusion of allogeneic CS1-specific universal CAR-expressing T lymphocytes UCARTCS1A, these cells target and bind to cancer cells expressing CS1. This induces selective toxicity in and causes lysis of CS1-expressing tumor cells. SLAMF7 is a member of the signaling lymphocytic activation molecule (SLAM) family of transmembrane receptors that modulate the function of immune cells through immunoreceptor tyrosine-based switch motifs (ITSMs) and intracellular adaptor proteins. SLAMF7 is highly expressed on certain malignant plasma cells and is minimally expressed on healthy immune cells.
Synonym:allogeneic gene-edited CAR T cells UCARTCS1A
allogeneic TALEN gene-edited CAR T cells UCARTCS1A
allogenic engineered T cells expressing anti- CS1 CAR UCARTCS1A
UCARTCS1A cells
Code name:UCART CS1A
UCART-CS1A
UCARTCS1A
Search NCI's Drug Dictionary